Seattle, WA, United States
Seattle, WA, United States

Sinovac Biotech Ltd. is a biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. The company is based in Beijing, China. Sinovac's commercialized vaccines include Healive , Bilive , Anflu , Panflu and PANFLU.1 . Sinovac is currently developing Universal Pandemic Influenza vaccine and Japanese encephalitis vaccine.Sinovac is developing vaccines for enterovirus 71, universal pandemic influenza, Japanese encephalitis, and human rabies. Its wholly owned subsidiary, Tangshan Yian, is conducting field trials for independently developed inactivated animal rabies vaccines. Wikipedia.


Time filter

Source Type

News Article | May 1, 2017
Site: en.prnasia.com

BEIJING, May 1, 2017 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, has filed a Form 12b-25 Notification of Late Filing with the U.S. Securities and Exchange Commission that discloses that the Company is unable to file its annual report on Form 20-F for the year ended December 31, 2016 (the "2016 Annual Report") within four months after the end of year 2016. Additional time is needed by the Company's Audit Committee in its internal investigation related to a recent report regarding the allegations raised in a research report by Geoinvesting. The investigation has slowed completion of the Company's financial statements and audit for the year ended December 31, 2016. The filing of Sinovac's 2016 Annual Report is delayed as a result. Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacturing, and commercialization of vaccines that protect against human infectious diseases. Sinovac's product portfolio includes vaccines against hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), mumps and canine rabies. In 2009, Sinovac was the first company worldwide to receive approval for its H1N1 influenza vaccine, which it has supplied to the Chinese Government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine to the government stockpiling program. Sinovac's newly developed innovative vaccine against HFMD caused by EV71 is ready for market launch. The Company is currently developing a number of new products including a Sabin-strain inactivated polio vaccine, pneumococcal polysaccharides vaccine, pneumococcal conjugate vaccine and varicella vaccine. Sinovac primarily sells its vaccines in China, while also exploring growth opportunities in international markets. The Company has exported select vaccines to 10 countries in Asia and South America. For more information, please visit the Company's website at www.sinovac.com. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/sinovac-reports-announces-filing-extension-for-2016-annual-report-300448552.html


LOS ANGELES--(BUSINESS WIRE)--Goldberg Law PC, a national shareholder rights litigation firm, announces that it is investigating Sinovac Biotech Ltd. (“Sinovac” or the “Company”) (Nasdaq: SVA) concerning possible violations of federal securities laws. If you purchased or otherwise acquired Sinovac Biotech Ltd. shares and would like more information regarding the investigation, we encourage you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights without cost to you. You can also reach us through the firm’s website at http://www.Goldberglawpc.com, or by email at info@goldberglawpc.com. On December 21, 2016, SeekingAlpha.com published an article revealing that according to a recent Beijing court judgment, Weidong Ying, Chairman and CEO of Sinovac, paid bribes to Yin Hongzhang, the Deputy Director General of the Center for Drug Evaluation for the China Food and Drug Administration, and his wife, in order to assist its vaccine clinical trial and approval. If you have any questions concerning your legal rights, please immediately contact Goldberg Law PC at 800-977-7401, or visit our website at http://www.Goldberglawpc.com, or email us at info@goldberglawpc.com. Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.


LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of Sinovac Biotech Ltd. (“Sinovac” or the “Company”) (NASDAQ: SVA) investors concerning the Company and its officers’ possible violations of federal securities laws. GPM is preparing a lawsuit on behalf of Sinovac investors. Sinovac is a biopharmaceutical company that engages in the research, development, manufacture and commercialization of vaccines against hepatitis A, hepatitis B, seasonal influenza, H5N1 and H1N1 pandemic influenza and mumps in the People's Republic of China. On December 21, 2016, media outlet SeekingAlpha issued a report disclosing that Sinovac’s Chairman and CEO, Weidong Ying, had paid bribes to Yin Hongzhang, the Deputy Director General of the Center for Drug Evaluation for the China Food and Drug Administration, to help procure and pass drug applications and evaluations. If you purchased Sinovac securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at http://www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.


News Article | November 14, 2016
Site: www.marketwired.com

FRANKLIN, INDIANA--(Marketwired - Nov. 14, 2016) - IBC Advanced Alloys Corp. ("IBC" or the "Company") (TSX VENTURE:IB)(OTCQB:IAALF) announces that David Anderson, the Company's current Vice President of Finance, has been appointed as Chief Financial Officer, replacing Simon Anderson, who has joined the Company's Board of Directors. David Anderson (no relation to Simon Anderson) is a Certified Management Accountant with over 20 years of progressive experience with public and private manufacturing companies, including in mergers and acquisition. He has worked at IBC and its predecessor company since 2007, serving in a variety of accounting, human resources, and information technology roles. David received his BA in Accounting from the University of Indianapolis. Simon Anderson has served since 2007 as Chief Financial Officer for IBC and its predecessor company. A CPA, CA with 30 years' experience, he has worked as an officer or director of public companies on the TSX Venture Exchange, TSX Exchange, and NASDAQ for almost 20 years. He has extensive experience in financing, mergers and acquisitions, corporate governance, and securities regulation practices, and he worked for nine years in business valuation with BDO Canada LLP. Currently a director of Sinovac Biotech Ltd. (NASDAQ: SVA), Simon received his Bachelor of Commerce in Accounting and Management Information Systems from the University of British Columbia. "The Board and I are very pleased with the addition of Simon Anderson to our Board of Directors and with David Anderson's appointment as Chief Financial Officer," said Major General Duncan Heinz (USMC, ret.), IBC's President and CEO. "Both of these individuals know our Company and the industries we serve extraordinarily well, and they have decades of experience between them in the finance, accounting, securities regulation, and business development fields. I am grateful that the Company will continue to benefit from their experience and their dedication to ensuring that IBC continues to meet our customers' needs and continues to build shareholder value." Simon Anderson's appointment to the IBC Board follows the October 31, 2016 resignation from the Board of Anthony Dutton, the Company's former President and CEO. "I want to once again thank Anthony for his years of service and his unflagging commitment to the success of IBC," General Heinz said. "We are poised today for growth and long-term success due in good measure to Anthony's many years of leadership and hard work in building up this Company." On Behalf of the Board of Directors: IBC is a leading beryllium and copper advanced alloys company serving a variety of industries such as defense, aerospace, automotive, telecommunications, precision manufacturing, and others. IBC's Copper Division manufactures and distributes a variety of copper alloys as castings and forgings, including beryllium copper, chrome copper, and aluminum bronze. IBC's Engineered Materials Division makes the Beralcast® family of alloys, which can be precision cast and are used in an increasing number of defense, aerospace, and other systems, including the F-35 Joint Strike Fighter. IBC's has production facilities in Indiana, Massachusetts, Pennsylvania, and Missouri. The Company's common shares are traded on the TSX Venture Exchange under the symbol "IB" and the OTCQB under the symbol "IAALF". This news release was prepared by management of IBC, which takes full responsibility for its contents. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy of this news release. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


News Article | November 7, 2016
Site: en.prnasia.com

BEIJING, Nov 7, 2016 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced the results of the Company's 2016 Annual General Meeting of Shareholders held on Monday, November 7, 2016 in Beijing, PRC. The required quorum, a majority of the common shares outstanding, was voted by proxy. The Company's shareholders approved the following proposals: Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacturing, and commercialization of vaccines that protect against human infectious diseases. Sinovac's product portfolio includes vaccines against hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), mumps and canine rabies. In 2009, Sinovac was the first company worldwide to receive approval for its H1N1 influenza vaccine, which it has supplied to the Chinese Government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine to the government stockpiling program. Sinovac's newly developed innovative vaccine against HFMD caused by EV71 is ready for market launch. The Company is currently developing a number of new products including a Sabin-strain inactivated polio vaccine, pneumococcal polysaccharides vaccine, pneumococcal conjugate vaccine and varicella vaccine. Sinovac primarily sells its vaccines in China, while also exploring growth opportunities in international markets. The Company has exported select vaccines to Mexico, Mongolia, Nepal, Tajikistan, Bangladesh, Chile and the Philippines, and was recently granted a license to commercialize its influenza vaccine in Guatemala. For more information, please visit the Company's website at www.sinovac.com. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/sinovac-announces-results-of-2016-annual-general-meeting-of-shareholders-300358151.html


News Article | November 28, 2016
Site: en.prnasia.com

BEIJING, Nov 28, 2016 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today its unaudited third quarter ended September 30, 2016. Mr. Weidong Yin, Chairman, President and CEO of the Sinovac, commented, "Our third quarter revenue rebounded from a slower first half of the year, increasing 71.4% to $28.7 million from $16.8 million from the same period of 2015. The sales improvement was mainly attributable to the newly introduced EV71 vaccine product sales, which contributed approximately $16.5 million to our quarterly revenue, partially offset by Bilive and Anflu revenue decreases." "Vaccine deliveries resumed in the third quarter after the interpretation of new government regulation was issued in June, however we expect the market for conventional vaccines to take longer to fully recover. Our Bilive sales decline was due to increased sales returns as the delayed supply reduced the shelf life of the vaccine in the channel, while our Anflu sales decline was a result of less vaccine produced during this challenging environment." "We continued to make progress on our pipeline programs with the continuation of clinical trials of our varicella vaccine, Sabin IPV (sIPV) and pneumococcal polysaccharide vaccine (PPV). Heading into the fourth quarter, we expect EV71 vaccine sales to remain our leading revenue contributor," concluded Mr. Yin. As in prior years, Sinovac submitted bids of its Healive in Beijing, Shanghai, and Jiangsu Province, and Anflu in Beijing. Sinovac won the tenders to supply Beijing with Healive over the course of 2016 to 2018 and Anflu for 2016. The total value of the tenders was RMB 32 million ($4.8 million) for Healive and RMB 6.6 million ($1.0 million) for Anflu. Sinovac was selected to be the sole supplier of Healive to Shanghai for 2016 and the value of the contract is RMB 14.1 million ($2.1 million). Sinovac won the tender to supply Healive to Jiangsu for 2016 and the total value of the tender was RMB 13.2 million ($2.0 million). Varicella - The vaccine candidate was approved to commence human clinical trials in 2015. The phase I trial was completed and the results demonstrated a positive safety profile of the vaccine candidate. The phase III trial commenced in the third quarter. A phase III trial measures efficacy and immunogenicity with a randomized, double-blind, parallel-treatment, placebo-controlled study in addition to safety. Over 6,000 subjects aged one to twelve years old were enrolled as volunteers for the phase III clinical trial. We expect the phase III clinical trial to be completed in the third quarter of 2017, after which the production license application will be filed with the CFDA. sIPV - The Company initiated the phase I clinical trial in October 2016. The preliminary results show a positive safety profile of the vaccine candidate. After the results were collected, Sinovac recently commenced the phase II trial, which is designed to study the immunogenicity of vaccine candidates with different levels of dosage content for the dose selection, and to further observe the safety of the vaccine. The phase II clinical trial is expected to be completed in the third quarter of 2017. Quarterly sales from continuing operations were $28.7 million compared to $16.8 million in the prior year period. Sales increased primarily due to revenue generated by the Company's EV71 vaccine. Gross profit from continuing operations was $23.0 million, compared to gross profit of $11.2 million in the prior year period. The increase was primarily due to the contribution of EV71 vaccine sales in the third quarter of 2016. Gross margin was 80.1%, compared to 66.9% in the prior year period. Selling, general and administrative expenses in the third quarter of 2016 were $12.3 million, compared to $10.0 million in the same period of 2015. The Company's selling, general and administrative expenses increased with the higher level of sales activity, and the Company also incurred a cost of $733 thousand relating to the proposed privatization of Sinovac. R&D expenses in the third quarter of 2016 were $4.2 million, compared to $2.2 million in the same period of 2015. The increase was mainly due to higher R&D expenses on the varicella and sIPV vaccine projects in the third quarter of 2016. Income from continuing operations was $4.3 million compared to a loss of $1.8 million in the prior year period. In addition, the third quarter of 2015 included a loss from discontinued operations of $183 thousand whereas no such income or loss was received in the third quarter of 2016. Net income attributable to common shareholders was $3.2 million, or $0.06 per basic and diluted share, compared to net loss attributable to common shareholders of $1.6 million, or ($0.03) per basic and diluted share in the prior year period. Non-GAAP EBITDA was $7.7 million in the third quarter of 2016, compared to $721 thousand in the prior year period. Non-GAAP net income from continuing operations in the third quarter of 2016 was $4.6 million, compared to a net loss of $1.2 million in the prior year period. Non-GAAP diluted earnings per share from continuing operations in the third quarter of 2016 was $0.06, compared to net loss of $0.01 per share in the prior year period. Reconciliations of non-GAAP measures to the nearest comparable GAAP measures are included at the end of this earnings announcement. Sales from continuing operations were $41.1 million for the nine months ended September 30, 2016, a decrease of 7.6% from $44.5 million in the prior year period. Excluding H5N1 revenue, sales from continuing operations were $34.7 million for nine months ended September 30, 2016, a decrease of 22.0% from $44.5 million in the prior year period. The sales decrease was due to lower sales to customers in the first half of 2016 and an increase in sales returns as a result of the vaccine incident in Shandong province. Gross profit from continuing operations was $27.0 million, a decrease of 19.0% from $33.3 million in the prior year period. Gross margin was 65.7%, compared to 74.9% in the prior year period. Excluding H5N1, gross margin was 67.0% for the nine months ended September 30, 2016, compared to 75.5% in the prior year period. The decrease was mainly due to a higher inventory provision provided for hepatitis A&B and mumps vaccines, higher idle capacity costs charged to cost of sales, and a negative gross profit for the hepatitis A&B vaccine due to higher sales returns provision provided in the period. Selling, general and administrative expenses for the nine months ended September 30, 2016 were $26.7 million, compared to $25.8 million in the same period of 2015. R&D expenses for the nine months ended September 30, 2016 were $9.1 million, compared to $6.6 million in the same period of 2015. The increase was mainly due to higher R&D expenses on the varicella and sIPV vaccines and the MMR vaccine project. Net loss from continuing operations was $9.9 million, compared to $749 thousand in the prior year period. Net income from discontinued operations was $2.3 million, compared to a net loss of $619 thousand in the prior year period. Net loss attributable to common shareholders was $5.0 million or ($0.09) per basic and diluted share for the nine months ended September 30, 2016, compared to net loss attributable to common shareholders of $1.6 million, or ($0.03) per basic and diluted share for the nine months ended September 30, 2015. Non-GAAP EBITDA was negative $4.3 million for nine months ended September 30, 2016, compared to $6.7 million in the prior year period. Non-GAAP net loss from continuing operations for the nine months ended September 30, 2016 was $8.5 million, compared to a net income of $168 thousand in the prior year period. Non-GAAP diluted net loss per share from continuing operations for the nine months ended September 30, 2016 was $0.11, compared to $0.00 per share in the prior year period. Reconciliations of non-GAAP measures to the nearest comparable GAAP measures are included at the end of this earnings announcement. As of September 30, 2016, cash and cash equivalents totaled $54.3 million, compared to $63.8 million as of December 31, 2015. For the nine months ended September 30, 2016 net cash used in operating activities was $15.5 million. Net cash used in investing activities was $7.4 million, which was for the purchase of equipment. Net cash provided by financing activities was $13.9 million, including loan proceeds of $35.0 million and loan repayment of $21.3 million. As of September 30, 2016, the Company had $29.4 million of bank loans due within one year. The Company expects that its current cash position will be able to support its operations for at least the next 12 months. The Company will seek new commercial bank loans to finance the commercialization of its pipeline products and for other operational purposes when appropriate. Update on Consideration of "Going Private" Proposals An independent special committee of the Company's Board of Directors is continuing its work to consider and evaluate competing proposals to privatize the Company. As disclosed previously, the Company's Board of Directors formed the special committee following the receipt of a non-binding "going private" proposal, dated January 30, 2016, from Mr. Weidong Yin, chairman, president and chief executive officer of the Company, and SAIF Partners IV L.P. and/or its affiliates. Subsequently, the special committee received a non-binding competing "going private" proposal, dated February 3, 2016, from a consortium comprised of PKU V-Ming (Shanghai) Investment Holdings Co., Ltd., Shandong Sinobioway Biomedicine Co., Ltd., CICC Qianhai Development (Shenzhen) Fund Management Co., Ltd., Beijing Sinobioway Group Co., Ltd., Heng Feng Investments (International) Limited and Fuerde Global Investment Limited. The special committee has implemented a customary process to ensure a fair assessment of both proposals. The special committee continues to carefully consider and evaluate both proposals with the assistance of the special committee's financial and legal advisors. No final decisions have been made with respect to either proposal, and there can be no assurance that any definitive and binding offer will be made, that any agreement will be executed or that either proposal or any other transaction will be approved or consummated. The Company does not undertake any obligation to provide any updates with respect to these or any other transactions, except as required under applicable law. Sinovac will host a conference call on Monday, November 28, 2016, at 8:00 a.m. EDT (Monday, November 28 at 9:00 p.m. China Standard Time) to review the Company's financial results and provide an update on recent corporate developments. To access the conference call, please dial 1-877-407-9039 (USA) or 1-201-689-8470 (International). A replay of the call will be available after the earnings call through December 12, 2016. To access the replay, please dial 1-877-870-5176 (USA) or 1-858-384-5517 (International) and reference the replay pin number 13650180. Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacturing, and commercialization of vaccines that protect against human infectious diseases. Sinovac's product portfolio includes vaccines against hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), mumps and canine rabies. In 2009, Sinovac was the first company worldwide to receive approval for its H1N1 influenza vaccine, which it has supplied to the Chinese Government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine to the government stockpiling program. Sinovac's newly developed innovative vaccine against HFMD caused by EV71 is ready for market launch. The Company is currently developing a number of new products including a Sabin-strain inactivated polio vaccine, pneumococcal polysaccharides vaccine, pneumococcal conjugate vaccine and varicella vaccine. Sinovac primarily sells its vaccines in China, while also exploring growth opportunities in international markets. The Company has exported select vaccines to Mexico, Mongolia, Nepal, Tajikistan, Bangladesh, Chile and the Philippines, and was recently granted a license to commercialize its influenza vaccine in Guatemala. For more information, please visit the Company's website at www.sinovac.com. This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward looking statements. Factors that might cause such a difference include our inability to compete successfully in the competitive and rapidly changing marketplace in which we operate, failure to retain key employees, cancellation or delay of projects and adverse general economic conditions in the United States and internationally. These risks and other factors include those listed under "Risk Factors" and elsewhere in our Annual Report on Form 20-F as filed with the Securities and Exchange Commission. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expects," "intends," "plans," "anticipates," "believes," "estimates," "predicts," "potential," "continue," or the negative of these terms or other comparable terminology. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. The Company assumes no obligation to update the forward-looking information contained in this release. To supplement its consolidated financial statements, which are prepared and presented in accordance with GAAP, Sinovac uses the following non-GAAP financial measures: non-GAAP EBITDA, non-GAAP net income from continuing operations and non-GAAP diluted EPS from continuing operations. For more information on these non-GAAP financial measures, please refer to the table captioned "Reconciliations of non-GAAP Measures to the Nearest Comparable GAAP Measures" in this results announcement. Sinovac believes that non-GAAP EBITDA, non-GAAP net income from continuing operations and non-GAAP diluted EPS from continuing operations help identify underlying trends in its business that could otherwise be distorted by the effect of certain income or expenses that Sinovac includes in income from operations from continuing operations, net income from continuing operations and diluted EPS from continuing operations. Sinovac believes that non-GAAP EBITDA, non-GAAP net income from continuing operations and non-GAAP diluted EPS from continuing operations provide useful information about its core operating results, enhance the overall understanding of its past performance and future prospects and allow for greater visibility with respect to key metrics used by our management in its financial and operational decision-making. Non-GAAP EBITDA, non-GAAP net income from continuing operations and non-GAAP diluted EPS from continuing operations should not be considered in isolation or construed as an alternative to income from operations from continuing operations, net income from continuing operations, diluted EPS from continuing operations, or any other measure of performance or as an indicator of Sinovac's operating performance. These non-GAAP financial measures presented here may not be comparable to similarly titled measures presented by other companies. Other companies may calculate similarly titled measures differently, limiting their usefulness as comparative measures to our data. Non-GAAP EBITDA represents income (loss) from continuing operations, excludes interest and financing expenses, interest income, net other income (expenses) and income tax benefit (expenses), and certain non-cash expenses, consisting of stock-based compensation expenses, amortization and depreciation that Sinovac does not believe are reflective of the core operating performance during the periods presented. Non-GAAP net income from continuing operations represents net income from continuing operations before stock-based compensation expenses, and foreign exchange gain or loss. Non-GAAP diluted EPS from continuing operations represents non-GAAP net income attributable to ordinary shareholders from continuing operations divided by the weighted average number of shares outstanding during the periods on a diluted basis, including accounting for the effect of the assumed conversion of options. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/sinovac-reports-unaudited-third-quarter-2016-financial-results-300368800.html


News Article | December 28, 2016
Site: marketersmedia.com

The analysts forecast the global human vaccines market to grow at a CAGR of 11.69% during the period 2016-2020. According to the Centers for Disease Control and Prevention (CDC), a vaccine is a product that stimulates a person’s immune system to produce immunity to a specific disease, protecting the person from that disease. Vaccines are usually administered through needle injections, but can also be administered by mouth or sprayed into the nose. Human vaccines are of two types: preventable human vaccines and therapeutic human vaccines. Preventable human vaccines are used both for adults and children. Pediatric human vaccines are used to immunize children against various infectious diseases such as diphtheria, influenza, hepatitis, pneumococcal diseases, and meningococcal diseases. For more information or any query mail at sales@wiseguyreports.com The report covers the present scenario and the growth prospects of the global human vaccines market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of preventable and therapeutic human vaccines. The market is divided into the following segments based on geography: • Americas • APAC • Europe The report, Global Human Vaccine Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. Other prominent vendors • Abbott • AstraZeneca • Bavarian Nordic • Baxter • Bharat Biotech • Bharat Immunologicals and Biologicals • bioCSL • Bio Med • Crucell • Dynavax Technologies • Indian Immunologicals • Janssen Pharmaceuticals • Kaketsuken • LG Life Sciences • Mitsubishi Tanabe Pharma • Lupin • Nuron • Novartis • Protein Sciences Corporation • Panacea Biotec • Roche • Serum Institute of India • Shenzhen Kangtai Biological Products • Sinovac Biotech • S K Chemicals • Takeda Pharmaceutical • Valeant Pharmaceuticals • Zydus Cadila Market driver • Growing awareness about vaccination and immunization programs • For a full, detailed list, view our report Market trend • Increase in strategic alliance and M&A • For a full, detailed list, view our report Key questions answered in this report • What will the market size be in 2020 and what will the growth rate be? • What are the key market trends? • What is driving this market? • What are the challenges to market growth? • Who are the key vendors in this market space? • What are the market opportunities and threats faced by the key vendors? • What are the strengths and weaknesses of the key vendors? For more information or any query mail at sales@wiseguyreports.com ABOUT US: Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports features an exhaustive list of market research reports from hundreds of publishers worldwide. We boast a database spanning virtually every market category and an even more comprehensive collection of market research reports under these categories and sub-categories. For more information, please visit https://www.wiseguyreports.com


News Article | November 9, 2016
Site: www.newsmaker.com.au

The report provides comprehensive information on the therapeutics under development for Rotavirus Infections  ,complete with analysis by stage of development,drug target,mechanism of action (MoA),route of administration (RoA) and molecule type. The report also coversthe descriptive pharmacological action of the therapeutics,its complete research and development history and latest news and press releases. Additionally,the report provides an overview of key players involved in therapeutic development for Rotavirus Infections   and features dormant and discontinued projects. The report helps in identifying and tracking emerging players in the market and their portfolios,enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Complete report on Rotavirus Infections - Pipeline Review,H2 2016 addition with 26 market data tables and 13 figures, spread across 62 pages is available at http://www.rnrmarketresearch.com/rotavirus-infections-pipeline-review-h2-2016-market-report.html This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases,company/university websites,clinical trial registries,conferences,SEC filings,investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally,various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Beijing Minhai Biotechnology Co., Ltd,Bharat Biotech International Limited,Biological E. Limited,Curevac AG ,Medicago Inc. ,MSD Wellcome Trust Hilleman Laboratories Pvt Ltd,Nanotherapeutics, Inc.,Serum Institute of India Limited,Shantha Biotechnics Limited,Sinovac Biotech Ltd.,Takeda Pharmaceutical Company Limited,Wuhan Institute of Biological Products Co., Ltd. Inquire before buying http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=748014(This is a premium report price at US$2000 for a single user PDF license).


MarketStudyReport.com adds “Global Travel Vaccines Market 2016-2020” new report to its research database. The report spread across 60 pages with table and figures in it. The Report analysts forecast the global travel vaccines market to grow at a CAGR of 6.83% during the period 2016-2020. About Travel Vaccines As the world continues to move toward globalization, the international travels will keep increasing. This fuels the demand for travel vaccines as the prevalence of infectious diseases are specifically region prone, unlike that of other indications. As vaccines are largely used as a preventive measure against these known infectious diseases, the travelers are advised to follow the region-specific immunization plan. The market is growing because various government bodies have mandated the immunization of travelers visiting the infectious-prone areas with various types of vaccines. This, in turn, prevents the spread of infection and averts any chances of epidemic outbreaks. Browse full table of contents and data tables at https://www.marketstudyreport.com/reports/global-travel-vaccines-market-2016-2020/ The report covers the present scenario and the growth prospects of the global travel vaccines market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of various vaccines administered to actively immunize meningococcal disease, Japanese encephalitis, rabies, typhoid, yellow fever, hepatitis B, and hepatitis A. The report also considers the revenues to be generated from the sales of vaccines that are expected to be launched into the market during the forecast period. The market is divided into the following segments based on geography:  Americas APAC EMEA The Report Global Travel Vaccines Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. Key vendors  GlaxoSmithKline Merck Pfizer Sanofi Other prominent vendors  Abbott AstraZeneca Bavarian Nordic Baxter Beijing Minhai Biotechnology Bharat Biotech Bharat Immunologicals and Biologicals Bio-Med Seqirus CSL Crucell CSL Dynavax Technologies Emergent BioSolutions GlycoVaxyn GreenSignal Bio Pharma Hualan Biological Engineering Imunoloski Zavod Indian Immunologicals Janssen Pharmaceuticals JN International Medical Kaketsuken LG Life Sciences Lupin Mitsubishi Tanabe Pharma Novavax Nuron Biotech Panacea Biotec Pfizer Protein Sciences Roche SK Chemicals Serum Institute of India Shenzhen Kangtai Biological Products Sinovac Biotech Takeda Pharmaceutical Vacunas Finlay Valeant Pharmaceuticals Valneva, Zydus Cadila Market driver  Growing demand among travelers  For a full, detailed list, view our report  Market challenge  Requires specific storage and distribution system  For a full, detailed list, view our report  Market trend  Combination vaccines For a full, detailed list, view our report  Key questions answered in this report  What will the market size be in 2020 and what will the growth rate be? What are the key market trends? What is driving this market? What are the challenges to market growth? Who are the key vendors in this market space? What are the market opportunities and threats faced by the key vendors? What are the strengths and weaknesses of the key vendors? To receive personalized assistance, write to us @ [email protected] with the report title in the subject line along with your questions or call us at +1 866-764-2150


News Article | November 15, 2016
Site: www.newsmaker.com.au

MarketStudyReport.com adds “Sinovac Biotech Ltd. – Product Pipeline Review – 2016” new report to its research database. The report spread across 32 pages with table and figures in it. The report Sinovac Biotech Ltd. - Product Pipeline Review - 2016, provides an overview of the Sinovac Biotech Ltd.s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Sinovac Biotech Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Browse full table of contents and data tables at https://www.marketstudyreport.com/reports/sinovac-biotech-ltd-product-pipeline-review-2016/ Scope - The report provides a snapshot of the pipeline therapeutic landscape of Sinovac Biotech Ltd. - The report provides overview of Sinovac Biotech Ltd. including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses Sinovac Biotech Ltd.s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features Sinovac Biotech Ltd.s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons to buy - Evaluate Sinovac Biotech Ltd.s strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Sinovac Biotech Ltd. - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Sinovac Biotech Ltd.s pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope To receive personalized assistance write to us @ [email protected] with the report title in the subject line along with your questions or call us at +1 866-764-2150

Loading Sinovac Biotech collaborators
Loading Sinovac Biotech collaborators